Free Newsletter
Wyeth, Solvay get FDA rejection
The FDA rejected the experimental antipsychotic bifeprunox, developed by Solvay Pharmaceuticals and its partner Wyeth. The companies failed to submit enough data to demonstrate that the schizophrenia remedy was effective, Solvay announced. It's a tough blow for the partnership, which had high hopes that bifeprunox would grow into a blockbuster product, and had planned to launch it in 2008.
In addition to efficacy data, the FDA wants to know more about the drug's metabolism in the human body and about the death of one trial participant, which Solvay termed "a complex case."
- see the release
- read this report for more
Related Articles:
ViroPharma's HCV drug shows promise. Report
Wyeth buying ViroPharma shares. Report
Four promising companies to watch. Report
More stories about FDA
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: